Mucin Site Specific O-glycosylation
Mucin Site Specific O-glycosylation
批准号:
7729223
负责人:
THOMAS A GERKEN
金额:
$27.6万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-05 至 2011-04-30
关键词:
AblationAcetylgalactosamineAffectAntigensBinding SitesBiochemicalBiologicalBiological ProcessBreastCA-125 AntigenCD8B1 geneCalcinosisCancer PatientCatalytic DomainCell CommunicationCell physiologyCell surfaceCellsCellular biologyChargeColitisCollaborationsColonColon CarcinomaColorectal NeoplasmsCommon NeoplasmComplementDetectionDevelopmentDiseaseDrug or chemical Tissue DistributionEnvironmentEnzymatic BiochemistryEnzyme KineticsEnzymesEpithelial CellsFamilyFundingGlycopeptidesGlycoproteinsGoalsHomologous GeneHumanIgA1Immune responseImmunoglobulin AIn VitroIndividualInflammatoryKineticsKnockout MiceKnowledgeLeadLectinLinkLocationMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMembrane ProteinsMethodsModalityModelingMuc 2 proteinMucin-1 Staining MethodMucin-2 Staining MethodMucinsMusMutateMutationN-acetylglucopyranosylamineNeoplasm MetastasisO-Glycans Biosynthesis PathwayP-selectin ligand proteinPTPRC genePatientsPatternPeptide HydrolasesPeptidesPhenotypePlayPolysaccharidesPost-Translational Protein ProcessingPredispositionPreventionProgress ReportsPropertyProtein IsoformsProteinsProteolysisResearchResearch DesignResistanceRoleSequence AnalysisSeriesSiteSorting - Cell MovementSpecificityStructureSubstrate SpecificitySyndromeTandem Repeat SequencesTertiary Protein StructureTransferaseTransforming Growth Factor beta ReceptorsTumor AntigensUnited States National Institutes of HealthWorkflygenome sequencingglycosylationglycosyltransferasehuman diseasein vivointerestknowledge baseloss of functionmalignant breast neoplasmmanmembermutantnovelnovel strategiespolypeptideppGalNAc-Tpreferenceprogramsprotein aminoacid sequencepublic health relevancereceptorstemsugartooltraffickingtumortumorigenesis
中文摘要
描述(由申请人提供):含有大量o糖基化粘蛋白结构域的糖蛋白具有重要的生物学作用,包括保护上皮细胞表面,调节细胞间相互作用以及调节炎症和免疫反应。它们在肿瘤发生和转移中起重要作用,是常见的肿瘤抗原。这些糖蛋白中的o -糖基化结构域是其正常生物学功能所必需的,主要是因为它们的延伸蛋白酶抗性结构是由o -聚糖赋予的。ppGalNAc转移酶的一个大家族(bbbb20个成员)通过将1- GalNAc添加到肽核的Ser或Thr残基上,启动o糖基化的第一步。随后的转移酶通过依次将糖添加到肽连接的GalNAc中来延长聚糖链。最近,一些ppGalNAc t的突变与结肠癌患者有关。由于结肠粘蛋白(MUC2)敲除小鼠很容易发生结肠癌,我们提出突变的h-ppGalNAc Ts不能正确地糖基化h-MUC2,导致结肠粘蛋白性质(或稳定性)改变,从而导致疾病倾向增加。在这项工作中,突变型和野生型转移酶的酶学和生物学特性将被表征,以了解它们的生物学功能(即在MUC2糖基化中的作用)和随后在疾病中的作用。预计这些研究将导致发现、预防和/或治疗结肠癌和其他疾病的潜在模式。在Aim 1中,将对一系列与人类疾病有关或具有显著有趣的生化或生物学特性的野生型ppGalNAc T肽和糖肽底物特异性进行表征。在Aim 2中,与结肠癌遗传相关的突变体ppGalNAc T's将进一步表征其酶学、底物特异性(包括MUC2)和一般细胞生物学(即亚细胞定位和分泌)。这一目的的目标是最终了解这些突变转移酶与MUC2糖基化和结肠癌的关系。这项工作也将提供这类转移酶的第一个详细的生化结构-功能分析。在Aim 3中,研究扩展到表征转移酶的糖肽底物偏好,这些转移酶将随后的糖转移到肽连接的GalNAc,即(2-Gal (1-3), 2-GlcNAc(1-3)和1-NeuNAc(2-6)),初始化o -聚糖生物合成的第一个延伸步骤。这些转移酶(即Core 1、Core 3和ST6GalNAc I和II转移酶)的改变也与疾病和各种癌症有关。通过这项工作,我们将对肽序列和局部环境对o -聚糖延伸初始步骤的调节作用有一个基本的了解。这项工作将有助于阐明这些转移酶的生物学作用及其对疾病的影响。这些研究也将产生用于合理预测位点特异性o糖基化的工具。公共卫生相关性:最近在结肠癌患者中发现了一系列糖基转移酶(蛋白糖基化酶)的突变。在这项工作中,我们将研究一系列突变型和野生型转移酶的酶学和生物学特性,以了解它们在该疾病中的生物学功能和作用。预计这些研究将导致发现、预防和/或治疗结肠癌和其他疾病的潜在模式。
英文摘要
DESCRIPTION (provided by applicant): Glycoproteins containing heavily O-glycosylated mucin domains play important biological roles including protecting epithelial cell surfaces, modulating cell-cell interactions and regulating the inflammatory and immune responses. They also play important roles in tumorigenesis and metastasis and are common tumor antigens. The O-glycosylated domains in these glycoproteins are required for their proper biological function, principally because of their extended protease resistant structures imparted by the O-glycans. A large family (>20 members) of ppGalNAc transferases initiates the first step of O-glycosylation by adding 1- GalNAc to Ser or Thr residues of the peptide core. Subsequent transferases elongate the glycan chain by sequentially adding sugars to peptide linked GalNAc. Recently mutations in a number of ppGalNAc Ts have been associated with patients with colon cancer. Since the colonic mucin (MUC2) knock-out mouse readily develops colon cancer, we propose that the mutated h-ppGalNAc Ts fail to properly glycosylate h-MUC2, resulting in a colonic mucin with altered properties (or stability) leading to an increased propensity for disease. In this work the enzymatic and biological properties of the mutant and wild type transferases will be characterized in order to understand their biological functions (i.e. role in MUC2 glycosylation) and subsequent role in disease. It is anticipated that these studies will lead to potential modalities for the detection, prevention, and/or treatment of colon cancer and other diseases. In Aim 1 ppGalNAc T peptide and glycopeptide substrate specificities will be characterized for a series of wild type ppGalNAc Ts that have been implicated in human disease or have significantly interesting biochemical or biological properties. In Aim 2 the mutant ppGalNAc T's, genetically linked to colon cancer, will be further characterized with respect to their enzymology, substrate specificities (including MUC2) and general cell biology (i.e. subcellular location and secretion). The goals of this aim will be to ultimately understand the association of these mutant transferases with MUC2 glycosylation and colon cancer. This work will also provide the first detailed biochemical structure-function analysis of this class of transferases. In Aim 3 studies are extended to characterize the glycopeptide substrate preferences of transferases that transfer subsequent sugars to the peptide linked GalNAc i.e. (2-Gal (1-3), 2-GlcNAc (1-3) & 1-NeuNAc (2-6)), initializing the first elongation steps of O-glycan biosynthesis. Alterations in these transferases (i.e. the Core 1, Core 3, and ST6GalNAc I & II transferases, respectively) also have associations with disease and various cancers. As a result of this work a basic understanding of the role of peptide sequence and local environment on the modulation of the initial steps of O-glycan elongation will be obtained. This work will contribute to the elucidation of the biological role(s) of these transferases and their impact on disease. Tools for the rational prediction of site specific O-glycosylation will also result from these studies. PUBLIC HEALTH RELEVANCE: Mutations in a series of glycosyltransferases (protein glycosylating enzymes) have recently been found in patients with colon cancer. In this work we will study the enzymatic and biological properties of a series of mutant and wild type transferases to understand their biological functions and roles in this disease. It is anticipated that these studies will lead to potential modalities for the detection, prevention, and/or treatment of colon cancer and other diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Initiation and regulation of mucin-type O-glycosylation
-
批准号:9012950
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and Regulation of Mucin-Type O-Glycosylation
-
批准号:10259867
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and Regulation of Mucin-Type O-Glycosylation
-
批准号:10424574
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and regulation of mucin-type O-glycosylation
-
批准号:8833545
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and regulation of mucin-type O-glycosylation
-
批准号:8990979
-
项目类别:
-
资助金额:$29.22万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and Regulation of Mucin-Type O-Glycosylation
-
批准号:10618405
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
Initiation and Regulation of Mucin-Type O-Glycosylation
-
批准号:10118475
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2015
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN GRANULES--ISOLATION AND CHARACTERIZATION
-
批准号:6301069
-
项目类别:
-
资助金额:$14.86万
-
财政年份:2000
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN SITE SPECIFIC O-GLYCOSYLATION
-
批准号:6497497
-
项目类别:
-
资助金额:$24.95万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN SITE SPECIFIC O-GLYCOSYLATION
-
批准号:6628160
-
项目类别:
-
资助金额:$25.7万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
Mucin Site Specific O-Glycosylation
-
批准号:7013227
-
项目类别:
-
资助金额:$26.89万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
Mucin Site Specific O-glycosylation
-
批准号:7816806
-
项目类别:
-
资助金额:$27.6万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN SITE SPECIFIC O-GLYCOSYLATION
-
批准号:6350316
-
项目类别:
-
资助金额:$24.22万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
Mucin Site Specific O-Glycosylation
-
批准号:7173721
-
项目类别:
-
资助金额:$26.11万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN GRANULES--ISOLATION AND CHARACTERIZATION
-
批准号:6201833
-
项目类别:
-
资助金额:$14.86万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN SITE SPECIFIC O-GLYCOSYLATION
-
批准号:6150048
-
项目类别:
-
资助金额:$23.52万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
Mucin Site Specific O-Glycosylation
-
批准号:6860149
-
项目类别:
-
资助金额:$27.54万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
Mucin Site Specific O-glycosylation
-
批准号:8271339
-
项目类别:
-
资助金额:$26.77万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
MUCIN SITE SPECIFIC O-GLYCOSYLATION
-
批准号:2848995
-
项目类别:
-
资助金额:$20.05万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
LINK PROTEIN DOMAIN STRUCTURE BY NMR
-
批准号:6201486
-
项目类别:
-
资助金额:$21.8万
-
财政年份:1999
-
负责人:THOMAS A GERKEN
-
依托单位:
海外基金